United Therapeutics (Nasdaq: UTHR) reported that treprostinil inhalation solution (Tyvaso) met the primary endpoint in the TETON-1 Phase III trial for idiopathic pulmonary fibrosis (IPF), producing a 130.1 mL absolute gain in forced vital capacity versus placebo at 52 weeks — a result that, combined with the earlier TETON-2 readout, gives the company a two-study package to support a supplemental NDA submission planned for this summer.
TETON-1 is a 598-patient, multicenter, randomized, double-blind, placebo-controlled registration study in IPF patients at US and Canadian sites, with full enrollment reached in January 2025. The primary endpoint was met, with a 130.1 mL improvement in forced vital capacity (FVC) versus placebo at 52 weeks (95% CI, 82.2 to 178.1 mL; p<0.0001). FVC measures the amount of air a patient can exhale and is a standard indicator of lung function in IPF. Tyvaso also significantly reduced the risk of clinical worsening and showed numerical improvements across several secondary measures, including time to acute exacerbation, lung function, and quality of life. An integrated analysis of TETON-1 and TETON-2 showed a combined FVC benefit of 111.8 mL versus placebo (95% CI, 79.7 to 144.0; p<0.0001). Overall survival at 52 weeks favored Tyvaso but was not statistically significant. The safety profile was consistent with prior studies, with no new safety signals identified.
The FVC effect size warrants some context. The two approved antifibrotics — nintedanib and pirfenidone, both cleared by the FDA in 2014 — are positioned around slowing the rate of FVC decline rather than producing an absolute gain versus placebo. Nintedanib's pivotal INPULSIS trials showed approximately 125 mL per year less decline versus placebo; pirfenidone's ASCEND trial showed a reduction in the proportion of patients with a decline of 10% or more. The TETON-1 absolute FVC figure of 130.1 mL at 52 weeks reflects a different endpoint framing, and cross-trial comparisons are limited by differences in patient populations, background therapy use, statistical methods, and endpoint definitions. Still, the direction and magnitude of the Tyvaso signal in a disease where functional decline is the norm is notable, and the consistency across two geographically distinct trials — TETON-1 in North America, TETON-2 internationally — strengthens the evidentiary base.
Tyvaso is a prostacyclin mimetic that activates the IP receptor (PTGIR) and, based on pharmacological profiling, broader prostanoid receptor pathways, increasing intracellular cAMP signaling to drive vasodilation and inhibit vascular smooth-muscle proliferation. The inhaled route delivers drug directly to the lung, and United Therapeutics has framed the mechanism as multimodal — acting across fibrotic, vascular, and inflammatory pathways simultaneously. That framing matters competitively because the three currently approved IPF agents (nintedanib, pirfenidone, and Boehringer Ingelheim's nerandomilast, cleared by the FDA in October 2025 as a preferential PDE4B inhibitor) are all oral, all antifibrotic-primary, and none directly engages the vascular remodeling component of IPF pathobiology. If the mechanism claim holds clinically, Tyvaso would occupy a genuinely distinct pharmacological niche in the IPF formulary. Cross-trial comparisons are limited, however, and the vascular differentiation argument will require more granular mechanistic data to fully evaluate.
The TETON program's design also addressed a practical clinical question: whether benefit persists in patients already receiving background antifibrotic therapy. Subgroup analyses showed consistent FVC effects regardless of whether patients were on nintedanib, pirfenidone, or no background therapy — positioning Tyvaso as a potential add-on rather than an alternative. None is currently positioned with a clearly established add-on IPF label comparable to what United is trying to build, and combination strategies in this disease have historically lacked a strong evidence base.